Table 2.
Cumulative incidence of recurrence in bone at any time in patients based on MAF expression (IHC)*
| Variable | Univariate (n = 343) | Multivariable (n = 343) | ||
|---|---|---|---|---|
| HR (95% CI) |
P | HR (95% CI) |
P | |
| Menopausal status | .676 | - | ||
| Premenopausal | 1.00 (referent) | - | ||
| Postmenopausal | 0.85 (0.40 to 1.80) |
- - |
||
| Tumor size, mm | .007 | .151 | ||
| ≤20 | 1.00 (referent) | 1.00 (referent) | ||
| 21–50 | 2.13 (1.03 to 4.37) |
2.21 (0.95 to 5.13) |
||
| >50 | 1.56 (0.54 to 4.47) |
2.34 (0.65 to 8.41) |
||
| Tumor grade | .046 | .121 | ||
| I | 1.00 (referent) | 1.00 (referent) | ||
| II | 1.42 (0.69 to 2.93) |
4.27 (0.55 to 32.99) |
||
| III | 1.27 (0.61 to 2.65) |
2.37 (0.28 to 19.68) |
||
| Lymph nodes | .007 | .047 | ||
| None | 1.00 (referent) | 1.00 (referent) | ||
| 1–3 | 1.06 (0.47 to 2.39) |
1.22 (0.49 to 3.02) |
||
| 4–9 | 0.63 (0.15 to 2.65) |
0.67 (0.14 to 3.23) |
||
| >9 | 5.14 (2.20 to 11.99) |
4.04 (1.46 to 11.15) |
||
| Hormonal receptor status | .167 | - | ||
| Negative | 1.00 (referent) | - | ||
| Positive | 0.58 (0.27 to 1.22) |
- - |
||
| HER2 status | .670 | - | ||
| Negative | 1.00 (referent) | - | ||
| Positive | 0.81 (0.31 to 2.13) |
- - |
||
| Proliferation (Ki-67) | .014 | .044 | ||
| Low proliferation (<15%) | 1.00 (referent) | 1.00 (referent) | ||
| High proliferation (≥15%) | 2.52 (1.23 to 5.18) |
2.23 (1.03 to 4.84) |
||
| cMAF (IHC) | 5x10−5 | 2x10−5 | ||
| Nonoverexpression | 1.00 (referent) | 1.00 (referent) | ||
| Overexpression | 4.68 (2.29 to 9.57) |
5.28 (2.50 to 11.20) |
||
* Measured from date of primary tumor surgical resection. Analyzed by Cox cause-specific hazards model with competing events (death before recurrence in bone). The risk of competing events is reported in Supplementary Table 4 (available online). CI = confidence interval; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio; IHC = immunohistochemistry.